MDSAP and FDA's Quality Management System Regulation (QMSR) were never meant to be competing frameworks, and since QMSR took effect on February 2, 2026, the practical distance between "MDSAP-compliant" and "QMSR-compliant" has gotten noticeably shorter. Here's what changed, what did not, and what it means for how you run your QMS.
The Path to Alignment
Both frameworks now sit on the same technical foundation. MDSAP has used ISO 13485:2016 as its core audit standard since the program began, layering on country-specific add-ons for each market a manufacturer includes in scope. QMSR did the same thing from the FDA side. It formally incorporated ISO 13485:2016 into 21 CFR 820, replacing the old Quality System Regulation and retiring legacy terminology like DMR and DHR in favor of ISO 13485's own language. The result is that a QMS built to satisfy MDSAP's ISO-13485-based model is, by construction, much closer to satisfying QMSR than it would have been under the old QSR.
MDSAP's own audit approach has been evolving in the same direction — moving away from QSR-specific references and toward an ISO-13485-first audit sequence, with FDA-specific items (certain labeling and recordkeeping requirements, for instance) checked as supplemental rather than foundational. The two programs are, in effect, converging on the same quality-system vocabulary.
FDA Policy – Clarified
QMSR did not change FDA's stance on MDSAP. The program remains voluntary, and FDA continues to accept MDSAP audit reports in place of routine surveillance inspections. That policy has one consistent carve-out — it does not extend to for-cause inspections, pre-approval inspections, or compliance follow-up, where FDA retains full inspection authority regardless of MDSAP status. QMSR also gave FDA investigators broader access to internal records that were previously less routinely reviewed, such as internal audit reports, supplier audit reports, management review records, which matters because MDSAP already operates with that same level of transparency. Manufacturers who have been through an MDSAP cycle are, in that specific sense, already used to the level of scrutiny QMSR brings to a standard FDA inspection.
Where Alignment Stops Short of Equivalence
It is worth being direct about this, because this is the part easiest to overstate: MDSAP alignment is not the same as QMSR compliance. QMSR still carries FDA-specific obligations that go beyond or are interpreted differently from ISO 13485, particularly around recordkeeping nuances and linkage to the FD&C Act. And MDSAP certification itself goes further than plain ISO 13485 certification in the other direction, layering in the regulatory requirements of up to five countries rather than just the US. So, the relationship is not really "MDSAP equals QMSR" in either direction. They are two overlapping but distinct compliance marks that happen to share a common technical backbone. FDA has been explicit that it will not rely solely on ISO 13485 or MDSAP results in place of its own oversight, even now. Treat MDSAP readiness as a strong lever for QMSR readiness, not a substitute for it.
Where the Overlap Is Strongest and Where FDA Looks Hardest
The processes MDSAP and QMSR both emphasize are the same ones that tend to generate FDA findings in general.
- CAPA and the explicit linkage from a nonconformity to verified effectiveness
- Risk management integration (ISO 14971) woven into day-to-day QMS activity rather than treated as a standalone exercise
- Design and development controls that give structured oversight of product design lifecycle
- Supplier management under a risk-based approach
- Robust complaint handling systems for capturing and addressing complaints
- Timely Medical Device Reporting (21 CFR 803) and corrections/removals (21 CFR 806).
If your MDSAP audit history demonstrates strength in these areas, it is a strong indicator of QMSR readiness, since FDA investigators consistently prioritize these same processes during inspections.
How to Leverage MDSAP for QMSR Compliance
Whether or not you formally participate in MDSAP, its structure is useful as a readiness tool:
- Build a crosswalk: Map QMSR provisions against ISO 13485 clauses and MDSAP processes, then layer in your SOPs and records. This becomes your master gap-assessment tool.
- Audit like FDA does: Use the MDSAP process sequence (Management; Measurement/Improvement; Design; Production; Purchasing) as the backbone of your internal audits, sampling CAPAs, complaints, supplier files, design records, and validations.
- Focus where it matters most: Prioritize CAPA, risk management, design controls, supplier oversight, and complaint/MDR handling — the areas FDA consistently scrutinizes.
- Choose your strategy: Decide whether to formally join MDSAP or simply mirror its structure internally. Both approaches work. The right choice depends on your target markets.
What This Means for Manufacturers
If your quality system has been built on the MDSAP model, you already have a strong foundation for QMSR. It speaks ISO 13485’s language and has been tested against a rigorous audit sequence. The task ahead is simply closing the FDA-specific gaps QMSR introduces, not rebuilding your entire system.
Talk to us about where your QMS stands against QMSR today.